Afya Ltd
AFYA
14.03
+0.13
+0.94%
Afya Ltd
US · AFYA
#3110 by market cap
Listed 2019
14.03
+0.13
+0.94%
Live - 5344 symbols - heartbeat 458s ago
· 2026-10-08 09:30
After-hours
13.90
0.00%
- Market cap
- 1.24B
- P/E (TTM)i
- 8.12
- P/Bi
- 1.35
- EPSi
- 1.64
- Div yieldi
- 4.78%
- 52W posi
- 53%
Reader sentiment
Are you bullish or bearish on AFYA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.52, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +11.89% YoY
Margins
- Gross margin
- 64.46%
- Operating margin
- 32.81%
- Net margin
- 20.35%
Key ratios & quality
- Enterprise valuei
- 2.23B
- PEG ratioi
- 0.31
- Altman Z-Scorei
- 1.52
PEG uses trailing P/E against the 3-year net income growth rate (26.29%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 333.94M | 750.63M | 1.20B | 1.72B | 2.33B | 2.88B | 3.30B | 3.70B |
| Gross profit | 165.88M | 441.78M | 766.54M | 1.07B | 1.47B | 1.77B | 2.09B | 2.38B |
| Selling & admin expenses | 70.03M | 239.12M | 402.86M | 622.62M | 798.15M | 940.13M | 1.01B | 1.11B |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 96.09M | 198.45M | 361.67M | 437.59M | 663.92M | 767.06M | 1.01B | 1.21B |
| Pretax profit | 98.72M | 186.94M | 335.05M | 273.46M | 428.43M | 429.58M | 676.39M | 860.95M |
| Tax | 3.99M | 14.18M | 27.07M | 31.18M | 35.68M | 24.17M | 27.47M | 92.50M |
| Net profit | 94.73M | 172.76M | 307.99M | 242.28M | 392.76M | 405.42M | 648.92M | 768.44M |
| Basic EPS | 1 | 2 | 3 | 2 | 4 | 4 | 7 | 8 |
| Diluted EPS | 0.98 | 2.02 | 3.12 | 2.37 | 4.12 | 4.27 | 6.93 | 8.24 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 936.36M | 919.40M | 928.51M | 912.99M | 1.01B | 972.10M |
| Gross profit | 653.72M | 576.69M | 588.59M | 564.36M | 698.06M | 598.71M |
| Selling & admin expenses | 264.94M | 276.38M | 286.16M | 285.59M | 287.66M | 286.34M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 372.53M | 285.23M | 277.36M | 278.48M | 393.60M | 297.86M |
| Pretax profit | 281.82M | 194.01M | 180.64M | 204.48M | 304.22M | 203.28M |
| Tax | 24.78M | 17.47M | 21.22M | 29.03M | 42.45M | 1.98M |
| Net profit | 257.04M | 176.54M | 159.42M | 175.44M | 261.76M | 201.29M |
| Basic EPS | 3 | 2 | 2 | 2 | 3 | 2 |
| Diluted EPS | 2.76 | 1.88 | 1.70 | 1.90 | 2.85 | 2.21 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 133.50M | 1.11B | 1.41B | 1.21B | 1.64B | 1.20B | 1.59B | 1.94B |
| Cash & ST investments | 62.26M | 943.21M | 1.05B | 748.56M | 1.09B | 553.03M | 911.02M | 1.13B |
| Inventory | 1.12M | 3.93M | 7.51M | 11.83M | 12.19M | -- | -- | -- |
| Total assets | 918.42M | 2.91B | 4.79B | 6.45B | 7.20B | 7.58B | 8.83B | 9.36B |
| Total current liabilities | 182.33M | 333.23M | 589.38M | 766.51M | 905.69M | 1.06B | 1.14B | 884.04M |
| Short-term debt | 26.80M | 76.30M | 179.64M | 168.15M | 239.84M | 216.15M | 409.13M | 116.44M |
| Long-term debt | 51.03M | 6.75M | 576.00M | 1.30B | 1.74B | 1.62B | 1.83B | 1.99B |
| Total liabilities | 328,064,000.00 | 798,727,000.00 | 1,959,313,000.00 | 3,447,388,000.00 | 3,949,381,000.00 | 3,941,469,000.00 | 4,518,956,000.00 | 4,466,749,000.00 |
| Total equity | 590.35M | 2.11B | 2.83B | 3.00B | 3.25B | 3.64B | 4.31B | 4.89B |
| Retained earnings | -- | 115.92M | 407.99M | 631.32M | 1.00B | 1.38B | 2.01B | 2.63B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.88B | 1.88B | 1.76B | 1.94B | 2.22B | 1.95B |
| Cash & ST investments | 1.15B | 1.10B | 996.83M | 1.13B | 1.33B | 1.01B |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 9.11B | 9.24B | 9.19B | 9.36B | 9.63B | 9.33B |
| Total current liabilities | 1.32B | 2.01B | 1.80B | 884.04M | 1.25B | 885.87M |
| Short-term debt | 421.04M | 1.27B | 969.39M | 116.44M | 187.58M | 183.99M |
| Long-term debt | 1.84B | 996.97M | 996.84M | 1.99B | 1.99B | 1.92B |
| Total liabilities | 4,670,459,000.00 | 4,601,380,000.00 | 4,400,567,000.00 | 4,466,749,000.00 | 4,838,953,000.00 | 4,397,813,000.00 |
| Total equity | 4.44B | 4.64B | 4.79B | 4.89B | 4.79B | 4.93B |
| Retained earnings | 2.13B | 2.31B | 2.46B | 2.63B | 2.58B | 2.78B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 80.32M | 299.22M | 371.51M | 630.87M | 843.90M | 1.04B | 1.43B | 1.53B |
| Depreciation & amortization | 9.08M | 73.15M | 108.74M | 154.22M | 206.22M | 289.51M | 333.34M | 373.34M |
| Free cash flow | 58.63M | 177.51M | 233.92M | 354.07M | 546.88M | 798.20M | 1.04B | 1.17B |
| Dividends paid | -- | -- | -- | 0 | 0 | 0 | 0 | 0 |
| Stock buybacks / issuance | 0 | 992.78M | 389.17M | -213.72M | -152.32M | -12.37M | 0 | -77.00M |
| Ending cash balance | 62.26M | 943.21M | 1.05B | 748.56M | 1.09B | 553.03M | 911.02M | 1.13B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 463.85M | 307.75M | 506.17M | 253.82M | 466.80M | 331.04M |
| Depreciation & amortization | 91.76M | 94.70M | 94.66M | 92.23M | 93.08M | 90.57M |
| Free cash flow | 407.64M | 178.89M | 428.09M | 152.97M | 422.02M | 255.86M |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock buybacks / issuance | 0 | 0 | -11.13M | -65.87M | -69.51M | -63.50M |
| Ending cash balance | 1.15B | 1.10B | 996.83M | 1.13B | 1.33B | 1.01B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 31.51 | 11.99 | 12.05 | 7.79 | 12.15 | 11.36 | 16.05 | 16.50 |
| ROA %i | 16.90 | 8.04 | 7.58 | 3.97 | 5.47 | 5.23 | 7.69 | 8.27 |
| ROIC %i | 26.83 | 13.13 | 10.91 | 7.94 | 11.13 | 11.80 | 13.72 | 12.67 |
| 5-year avg ROE %i | -- | -- | -- | 32.36 | 15.10 | 11.07 | 11.88 | 12.77 |
| EBIT margin %i | 30.28 | 32.29 | 33.72 | 26.12 | 30.79 | 28.37 | 31.56 | 35.17 |
| FCF / sales %i | 17.56 | 23.65 | 19.47 | 20.59 | 23.48 | 27.75 | 31.48 | 31.58 |
| Current ratioi | 0.73 | 3.34 | 2.38 | 1.57 | 1.81 | 1.14 | 1.39 | 2.20 |
| Quick ratioi | 0.67 | 3.23 | 2.32 | 1.50 | 1.74 | 1.08 | 1.34 | 2.13 |
| Debt / assetsi | 8.47 | 11.84 | 23.81 | 33.53 | 37.71 | 35.27 | 35.94 | 33.34 |
| LT debt / equityi | 10.17 | 13.01 | 34.57 | 67.62 | 77.36 | 68.28 | 64.74 | 61.91 |
| Interest coveragei | 42.07 | 4.37 | 5.79 | 2.56 | 2.48 | 2.11 | 2.85 | 2.96 |
| Revenue CAGR (3Y) %i | -- | -- | 77.17 | 72.68 | 45.85 | 33.78 | 24.33 | 16.65 |
| Net income CAGR (3Y) %i | -- | -- | 86.00 | 37.26 | 34.39 | 9.77 | 41.41 | 26.29 |
| FCF CAGR (3Y) %i | -- | -- | 131.51 | 82.10 | 45.51 | 50.55 | 43.22 | 28.77 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 16.56 | 16.19 | 16.47 | 16.50 | 16.56 | 16.49 |
| ROA %i | 8.10 | 8.12 | 8.15 | 8.27 | 8.09 | 8.43 |
| ROIC %i | 14.32 | 13.62 | 14.06 | 12.67 | 12.60 | 12.82 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 32.98 | 32.72 | 34.92 | 35.17 | 35.35 | 35.24 |
| FCF / sales %i | 32.67 | 30.92 | 33.67 | 31.58 | 31.32 | 32.90 |
| Current ratioi | 1.42 | 0.94 | 0.98 | 2.20 | 1.78 | 2.20 |
| Quick ratioi | 1.38 | 0.91 | 0.95 | 2.13 | 1.73 | 2.13 |
| Debt / assetsi | 35.14 | 34.91 | 32.38 | 33.34 | 33.26 | 33.43 |
| LT debt / equityi | 63.19 | 42.62 | 42.25 | 61.91 | 63.52 | 60.02 |
| Interest coveragei | 2.87 | 2.96 | 2.78 | 2.96 | 2.96 | 2.96 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Undergraduate is the largest reported line at 89.47% of revenue, across 4 reported segments.
- The next-largest line, Continuing Education, is a distant second at 6.68% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Undergraduate89.47%
Continuing Education6.68%
Medical practice solutions4.31%
Quote time 2026-10-08 09:30:57 · For reference only, not investment advice and not tailored to your situation.